# Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

> **NCT02616393** · PHASE2 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 36 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Leptomeningeal Metastases
- Brain Metastases

## Interventions

- **DRUG:** Tesevatinib

## Key facts

- **NCT ID:** NCT02616393
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-04-03
- **Final completion:** 2018-04-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616393, "Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02616393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*